Pacer Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pacer Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57K	Buy	+1,698	New	+$42.2K	﹤0.01%	2007
2024 Q3	–	Sell	-718	Closed	-$29.5K	–	2666
2024 Q2	$29.5K	Sell	718 -122	-15%	-$5.21K	﹤0.01%	3347
2024 Q1	$39.2K	Buy	+840	New	+$39.6K	﹤0.01%	3267
2021 Q2	–	Sell	-609	Closed	-$69K	–	1526
2021 Q1	$69K	Sell	609 -296	-33%	-$40.3K	﹤0.01%	1384
2020 Q4	$125K	Sell	905 -638	-41%	-$75.7K	﹤0.01%	1329
2020 Q3	$127K	Buy	+1,543	New	+$128K	﹤0.01%	1226
2018 Q4	–	Sell	-2,910	Closed	-$222K	–	932
2018 Q3	$222K	Buy	+2,910	New	+$237K	0.01%	1013
2018 Q1	–	Sell	-1,100	Closed	-$51K	–	1110
2017 Q4	$51K	Buy	+1,100	New	+$53.9K	﹤0.01%	1009
2017 Q3	–	Sell	-3,402	Closed	-$211K	–	1242
2017 Q2	$211K	Buy	3,402 +365	+12%	+$22K	0.02%	984
2017 Q1	$206K	Buy	3,037 +560	+23%	+$42.7K	0.03%	905
2016 Q4	$174K	Buy	2,477 +240	+11%	+$17K	0.02%	914
2016 Q3	$159K	Buy	2,237 +192	+9%	+$12.3K	0.02%	900
2016 Q2	$100K	Buy	+2,045	New	+$132K	0.02%	987

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Pacer Advisors's RARE Position: Q2 2026 in Review

Pacer Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 1,698 shares worth $57K. The stake represents ﹤0.01% of the portfolio and ranks #2007 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in RARE as recently as Q2 2024.

Pacer Advisors first reported a position in RARE in Q2 2016 and has held it in 13 quarters since. The position peaked at $222K in Q3 2018. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Pacer Advisors held 1,698 shares of Ultragenyx Pharmaceutical worth $57K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Pacer Advisors position in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2007 holding.
Pacer Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and has held it in 13 quarters since.
Pacer Advisors's Ultragenyx Pharmaceutical position peaked at $222K in Q3 2018.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.